Physician profile
Sarah E Jacobs
NPI 1063119758
$3,183.52
in general payments reported to CMS, 2019-2025
19 companies · $940 in 2025
The $940 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $980 · 2024: $1,264 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,225.66 | 2023-2025 | |
| Neos Therapeutics, LP | $391.34 | 2023-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $340.41 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $227.93 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $167.79 | 2023-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Corium, LLC | $167.68 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $105.57 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.77 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $85.83 | 2025 | Qelbree |
| Almatica Pharma LLC | $82.16 | 2023-2025 | Loreev Xr, Gralise |
| Tempus Ai, INC | $75.45 | 2024 | |
| Alkermes, INC. | $49.73 | 2024 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $28.66 | 2023 | Quviviq |
| Biogen, INC. | $24.99 | 2025 | Zurzuvae |
| Neurocrine Biosciences, INC. | $24.68 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $23.55 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.18 | 2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $20.90 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $16.24 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.